Pioneering the Use of Robotics and Flexible Instruments
TransEnterix® is a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery by addressing the economic and clinical challenges associated with current laparoscopic and robotic solutions. The company is focused on the development and commercialization of the SurgiBot® System, a minimally invasive surgical system that is designed to be operated through a single surgical incision.
U.S. Public Company (TRXC), Founded in 2006
TransEnterix was founded in 2006, and has successfully designed and received FDA clearance and European Certification (CE) on a suite of flexible instruments and the SPIDER® Surgical System. Development of the next generation robotic platform, the SurgiBot System, began in 2012.
TransEnterix is a US public company, headquartered in the Research Triangle of North Carolina, and is listed on the NYSE MKT Exchange (TRXC). We are a committed group of engineering, clinical, manufacturing and business professionals who seek to revolutionize how minimally invasive surgery is performed.
The SurgiBot™ System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory authorities for sale outside the United States.